SCHEMBL2236290

SCHEMBL2236290

Oc1cc(-c2nc(Nc3ccc4nc[nH]c4c3)c3ccccc3n2)cc(O)c1O

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 13/20 0.52
ABCB1 P08183 1/20 0.52
MEN1 O00255 6/20 0.51
KMT2A Q03164 6/20 0.51
MAPT P10636 3/20 0.51
GAA P10253 3/20 0.51
TP53 P04637 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
ULK1 O75385 1/20 0.47
PDK1 Q15118 1/20 0.47
ULK2 Q8IYT8 1/20 0.47
NTSR1 P30989 1/20 0.47
CDK1 P06493 1/20 0.47
GBA1 P04062 1/20 0.47
POLB P06746 1/20 0.47
ABCC1 P33527 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2231200 0.82 KDM1A (0.64) ABCG2ABCB1MAPTTP53SMN1; SMN2
SCHEMBL2296338 0.81 ABCG2 (0.70) ABCG2MEN1KMT2AMAPTGAA
SCHEMBL2298345 0.81 ROCK2 (0.54) ABCG2ABCB1MEN1KMT2AMAPT
SCHEMBL2294276 0.81 ABCG2 (0.78) ABCG2MEN1KMT2AMAPTGAA
SCHEMBL2295756 0.79 TGFBR1 (0.64) ABCG2ABCB1MEN1KMT2AMAPT
SCHEMBL2299801 0.78 ABCG2 (0.74) ABCG2MEN1KMT2AMAPTGAA
SCHEMBL2296472 0.78 ABCG2 (0.74) ABCG2ABCB1MEN1KMT2AMAPT
SCHEMBL22201474 0.76 HPGD (0.64) ABCG2ABCB1MEN1KMT2AMAPT
SCHEMBL2294947 0.76 ABCG2 (0.76) ABCG2ABCB1MEN1KMT2AMAPT
SCHEMBL2293460 0.75 MEN1 (0.69) ABCG2ABCB1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528606-B1 QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS LEVITZKI ALEXANDER (IL) 2014-09-24 EP disclosed
US-8759363-B2 Quinazoline-based T cell proliferation inhibitors YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2014-06-24 US disclosed
US-20130109706-A1 QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERSALEM LTD. (IL) 2013-05-02 US disclosed
EP-2528606-A1 QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) 2012-12-05 EP disclosed
WO-2011092695-A1 QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109706-A1 QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS IL2, CD4, NFATC1 ABCG2 2405/4885ABCB1 853/4885MEN1 3730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.